Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2025
Oruka Therapeutics, Inc. (ORKA)
Price$92.58Cached quote
Net income
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — |
| Research & development | $100.6M | $75.1M | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M | $7.1M | $5.6M | $2.9M | $1.1M | $2.3M | $3.1M | — | — | — | — | — | — |
| Operating expenses | $122.1M | $88.1M | $7.3M | $10.6M | $19.3M | $9.8M | $5.8M | $8.1M | $18.7M | $16.6M | $11.5M | $9.7M | $6.9M | $4.3M | $7.4M | $9.2M | — | — | — | — | — | — |
| Operating income | −$122.1M | −$88.1M | −$7.3M | −$10.6M | −$19.3M | −$9.8M | −$5.8M | −$8.1M | −$18.7M | −$16.6M | −$11.5M | −$9.7M | −$6.9M | −$4.3M | −$7.4M | −$9.2M | — | — | — | — | — | — |
| EBITDA | −$122.0M | −$88.1M | −$7.3M | −$10.6M | −$19.3M | −$9.8M | −$5.8M | −$8.1M | −$18.7M | −$16.6M | −$11.4M | −$9.7M | −$6.9M | −$4.3M | −$6.8M | −$8.8M | — | — | — | — | — | — |
| Net income | −$105.4M | −$83.7M | −$5.3M | −$9.9M | −$19.3M | −$9.7M | −$5.5M | −$7.9M | −$18.5M | −$16.4M | −$11.4M | −$9.7M | −$6.9M | −$4.3M | −$5.4M | −$8.4M | −$9.1M | −$19.4M | −$14.0M | −$5.2M | −$1.5M | −$511,000 |
| Basic EPSper basic share | -$1.85 | -$3.87 | -$0.37 | -$0.69 | -$1.39 | -$2.07 | -$4.15 | -$10.31 | -$31.86 | -$32.58 | -$32.76 | -$59.58 | -$131.04 | -$244.44 | -$404.46 | -$748.44 | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$1.85 | -$3.87 | -$0.37 | -$0.69 | -$1.39 | -$2.07 | -$4.15 | -$10.31 | -$31.86 | -$32.58 | -$32.76 | -$59.58 | -$131.04 | -$244.44 | -$404.46 | -$748.44 | — | — | — | — | — | — |
Owners
Reported shareholders
14.83%of listed shares
FMR LLC9.06M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.83%9.06M shares |
BlackRock, Inc. | 8.17%4.99M shares |
VHCP Management III, LLC / Venrock Healthcare Capital Partners III, L.P. / VHCP Management EG, LLC / VHCP Co-Investment Holdings III, LLC / Koh Bong Y / Shah Nimish P / Venrock Healthcare Capital Partners EG, L.P. | ≈6.79%4.15M shares |
Venrock Adviser, LLC | 6.79%4.15M shares |
Fairmount Funds Management LLC | 6.07%3.71M shares |
Capital World Investors | 5.57%3.4M shares |
RTW INVESTMENTS, LP | 5.14%3.14M shares |
STATE STREET CORP | 4.38%2.67M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.87%2.36M shares |
Paradigm Biocapital Advisors LP | 3.51%2.14M shares |
Janus Henderson Biotech Innovation Master Fund Ltd / JANUS HENDERSON GROUP PLC | ≈3.47%2.12M shares |
Deep Track Capital, LP | 3.15%1.93M shares |
Bellevue Group AG | 2.71%1.66M shares |
FRANKLIN RESOURCES INC | 2.66%1.62M shares |
Remedium Capital Partners, LLC | 2.56%1.57M shares |
RA CAPITAL MANAGEMENT, L.P. | 2.55%1.55M shares |
VIKING GLOBAL INVESTORS LP | 2.46%1.5M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.34%1.43M shares |
Jupiter Topco LLC | 2.25%1.38M shares |
PERCEPTIVE ADVISORS LLC | 2.20%1.35M shares |
Percentages use 61.07M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 699 | $82.15 | $57.4K | 15.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 888 | $80.01 | $71.0K | 16.0K |
| Jun 15, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 395 | $69.69 | $27.5K | 16.9K |
| Jun 15, 2026Form 4 · 10b5-1 | Goncalves JoanaChief Medical Officer | SellCommon Stock | 947 | $69.69 | $66.0K | 32.7K |
| Jun 15, 2026Form 4 · 10b5-1 | Goncalves JoanaChief Medical Officer | SellCommon Stock | 300 | $70.62 | $21.2K | 33.7K |